EUROPEAN COMMISSION
JOINT RESEARCH CENTRE

Directorate F – Health and Food
Disease Prevention

Annual Declaration of Interests[1] (DoI) form
(v2, 01 July 2026)

European Commission initiative on Lung Cancer (EC-LuC)

Please answer each of the questions below.
If the answer to any of the questions is "Yes"[2], please complete the corresponding fields, describing the circumstances, as appropriate.

If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the EC-LuC activities.
If you do not disclose relevant activities of interest for the EC-LuC, your role may be revised.

[1] According to EC's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 10, each member of an expert group has to complete a DoI form
https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en

[2] Answering "Yes" to the questions on this form does not automatically limit your participation in the EC-LuC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (*i.e.* any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

Name and Surname:	**ATOCHA ROMERO ALFONSO**

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
1. Do you have current investments[3] in a legal entity[4] with an interest related to lung cancer which either: • **has a value of more than 10.000 EUR, or** • **entitles you to a voting right of 5% or more?**	Yes ☐ No ☒	N/A	*Not applicable.*	*Not applicable.*
2. Within the past 5 years, were you employed (remunerated or non-remunerated post) or have you had any other professional relationship with a legal entity or any other body, with an interest related to lung cancer? **A. Employment**	Yes ☒ No ☐	02/2015–Present	• **Entity:** Hospital Universitario Puerta de Hierro Majadahonda. • **Place/type:** Majadahonda, Madrid, Spain; public healthcare institution. • **Remuneration:** Public employment; salary established under the applicable public-sector salary scale.	Technical Director and Head of the Liquid Biopsy Laboratory within the Medical Oncology Department. Responsible for molecular diagnostics, quality management, translational research, staff supervision and training.
B. Consultancy, including advisory activities	Yes ☒ No ☐	26/11/2024 22/05/2025 10/2024 2021	• **Janssen Pharmaceutica NV (Johnson & Johnson):** Beerse, Belgium; private; virtual advisory board; honorarium €1,104. • **Menarini Stemline España S.L.U.:** Badalona, Spain; private; in-person activity in San Sebastián; honorarium €1,076. • **Thermo Fisher Scientific:** private; virtual remunerated consultancy; amount below €500.	• Advisory board participation on liquid-biopsy concordance and its adoption in clinical practice. • Invited speaker on ESR1 mutation testing in liquid biopsy and critical quality-control points. • Scientific consultancy/advisory activity related to molecular diagnostics. • Scientific consultancy/advisory activity related to molecular diagnostics.

[3] **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (*e.g.*, proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).
[4] **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
			• **Health in Code:** Madrid, Spain; private; remunerated consultancy; amount below €500.	
C. Non-remunerated post	Yes ☐ No ☒	N/A	*Not applicable.*	*Not applicable.*
D. Legal representation[5]	Yes ☐ No ☒	N/A	*Not applicable.*	*Not applicable.*
3. Regarding research related to lung cancer within the past 5 years: **A. Have you been an investigator in research studies on lung cancer?**	Yes ☒ No ☐	01/2021–12/2025	• **PI24/01725 (2025–Present):** Role of gut microbiota in the response to chemoimmunotherapy in non-small-cell lung cancer — Principal Investigator. • **CPP2022-009545 STRAGEN-IO (2023–Present):** Clinical validation by liquid biopsy of a genetic and epigenetic prognostic signature for chemoimmunotherapy response — Co-Principal Investigator. • **GECP 2024/J&J (2024–Present):** Liquid-biopsy monitoring of EGFR-mutant NSCLC using ctDNA — Principal Investigator. • **PI21/01500 Biomarkers4Cure (2022–2025):** Predictive biomarkers of response to neoadjuvant immunotherapy plus chemotherapy in operable lung cancer — Principal Investigator. • **DTS21/00124 (2022–2024):** Detection of ALK translocations in plasma extracellular vesicles — Principal Investigator and multicentre coordinator. • **GECP/Roche III Early Forum (2023–2025):** Role of microbiota in response to neoadjuvant immunochemotherapy — Principal Investigator. • **ctDNA Centres of Excellence (2022–2025):** Circulating tumour DNA study — Principal Investigator. • **RTC2019-007359-1 BLI-O (2020–2023):** Liquid-biopsy molecular markers for long-term survival with immunotherapy — Co-Principal Investigator. • **PI17/01977 (2018–2021):** Clinical utility of liquid biopsy in EML4-ALK-positive NSCLC — Principal Investigator.	Translational and clinical lung-cancer research using ctDNA, extracellular vesicles, genomic and epigenomic signatures, and microbiota. Results from completed components have been published in peer-reviewed journals; ongoing studies are not yet fully published.

[5] **Legal representation** refers to the representation of natural or legal persons through other persons in accordance with national law. For example, the president of a company is the legal representative of that company.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
B. If yes, for the aforementioned research studies, did you receive support[6]?	Yes ☒ No ☐	01/2021–12/2025	• **Instituto de Salud Carlos III, Madrid, Spain (public):** PI24/01725, €340,000; DTS21/00124, €88,550; PI21/01500, €266,200; PI17/01977, institutional public grant. • **Spanish State Plan / EU NextGenerationEU (public):** CPP2022-009545 STRAGEN-IO, €307,324.70. • **Fundación GECP, Spain (non-profit), financed by Johnson & Johnson (private):** GECP 2024 EGFR/ctDNA study, €30,000. • **Fundación GECP, Spain (non-profit), with Roche funding (private):** III Early Forum microbiota study, €25,000. • **EMQN (non-profit), with AstraZeneca and MSD funding (private):** ctDNA Centres of Excellence Study, €45,000. • **Spanish State collaborative research programme (public):** RTC2019-007359-1 BLI-O; institutional grant support.	The amounts shown are institutional research-grant totals managed by Hospital Universitario Puerta de Hierro / IIS Puerta de Hierro–Segovia de Arana; they were not personal payments. The annual budget of the home institution is not available to the declarant. The study titles correspond to those listed in section 3A.
4. Do you have membership in national or international organisations[7], including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies or any decision making bodies with an interest in lung cancer?	Yes ☒ No ☐	05/2025–Present	• **CTN-UNE 129 "In vitro diagnostic systems and clinical laboratory":** Spain; national standardisation committee; non-remunerated member. • **ISO/TC 212/WG 4 "Microbiology and molecular diagnostics":** international standardisation working group; non-remunerated expert.	Provides technical input and participates in consensus-based standards development, including ISO/PWI/TS 25725, "Design and workflow requirements for NGS-based oncology applications". No commercial representation and no personal remuneration.
5. Do you have intellectual property rights (IPR)[8] related to lung cancer?	Yes ☐ No ☒	N/A	*Not applicable.*	*Not applicable.*
6. Within the past 5 years: **A. Have you provided any expert opinion or testimony in the field of lung cancer, for a legal**	Yes ☐ No ☒	N/A	*Not applicable.*	*Not applicable.*

[6] **Support** refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).

[7] **Organisation** refers to a governmental, international or non-profit organisation.

[8] **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
entity or other body as part of a regulatory, legislative or judicial process?				
B. Have you held an office or other position, paid or unpaid, where you represented interests or defended an opinion in the field of lung cancer?	Yes ☐ No ☒	N/A	*Not applicable.*	*Not applicable.*
7. Do any of your immediate family members[9] have direct interests related to lung cancer that could undermine your independence?	Yes ☐ No ☒	N/A	*Not applicable.*	*Not applicable.*
8. Within the past 5 years, did you take part in other activities with interests related to lung cancer?	Yes ☐ No ☒	N/A	*Not applicable.*	*Not applicable.*

[9] **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

Notes:

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published[10] before you send the DoI form to the Joint Research Centre (JRC), EC.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending an e-mail as soon as possible at: JRC-CANCER-POLICY-SUPPORT@ec.europa.eu.

☒ I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.
☒ I agree my DoI form to be publicly available on the EC's web-hub on cancer screening and care, during the EC-LuC membership.
☒ I am informed that my personal data are stored, processed and published by the EC in accordance with Regulation (EU) 2018/1725.

Name and Surname: Atocha Romero Alfonso **Date:** 24 July 2026

Signature: ROMERO ALFONSO ATOCHA - 51077900Y Firmado digitalmente por ROMERO ALFONSO ATOCHA - 51077900Y Fecha: 2026.07.24 19:26:30 +02'00' **Place:** Madrid

[10] Personal data processing including the DoI
https://ec.europa.eu/dpo-register/detail/DPR-EC-00656